Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Ovarian Cancer – Current Treatment – Current Treatment: Physician Insights – Ovarian Cancer (US)

Login to access report north_east
Contact sales account_box

Although chemotherapy has traditionally been the cornerstone of ovarian cancer treatment, angiogenesis and PARP inhibitors have revolutionized the treatment landscape, impacting prescribing decisions. The use of Lynparza (AstraZeneca / Merck & Co.), Zejula (GlaxoSmithKline), and Rubraca (Pharma&) as maintenance therapy across multiple lines and biomarker-defined patient populations is creating new sequencing dynamics. Elahere, set to be the standard of care for FRα-positive patients, is having an impact on the treatment algorithm for platinum-resistant disease.

Questions answered

  • What is the patient share of key therapies for advanced-stage ovarian cancer by line of therapy?
  • What factors influence physicians’ choice of first-line maintenance treatment (e.g., Lynparza plus bevacizumab versus Zejula) for advanced-stage ovarian cancer?
  • What are the key drivers of and barriers to the use of select drugs for advanced-stage ovarian cancer?
  • How do drug-treatment rates vary between key ovarian cancer patient populations, according to stage of disease and line of therapy?

Markets covered: United States

Primary research: Survey of 100 U.S. medical oncologists fielded in April 2024

Key drugs: bevacizumab, Lynparza, Zejula, Rubraca, and Elahere

Product description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
north_east
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
north_east
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…
north_east
Report
Type 2 Diabetes – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Metformin remains the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. More effective, safer, and…
north_east
Report
Atrial Fibrillation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Atrial Fibrillation (US)
Atrial fibrillation (AF) is a common arrhythmia characterized by irregular, often rapid heartbeats in the atria, increasing the risk of stroke and cardiovascular complications. Management typically…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east